TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24647921
Drug: Varenicline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (titrated to 2 mg)
Study: 8562040
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg EMD 55900
Study: 8562040
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg EMD 55900
Study: 8562040
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EMD 55900
Study: 2708742
Drug: Nicergoline (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (daily oral dose, 30 mg, and intravenous dose during dialyses, 5 mg)
Study: 2708742
Drug: Nicergoline (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (daily dose of 30 mg for 6 months after trial)
Study: 23124529
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group therapy (n = 33)
Study: 23124529
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy (n = 32)
Study: 21750426
Drug: Oxycodone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (15 mg, orally)
Study: 19841125
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy (initiated between 7 and 14 days of life)
Study: 11350509
Drug: Lidocaine/prilocaine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 30 seconds
Study: 11350509
Drug: Lidocaine/prilocaine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 2 minutes
Study: 11350509
Drug: Lidocaine/prilocaine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine gel (Oraqix) applied for 5 minutes
Study: 2558186
Drug: Pyridoxine (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (vitamin B6) 50 mg per day
Study: 765457
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate (Monistat Cream 2%) administered once daily at bedtime for 14 days
Study: 765457
Drug: Nystatin vaginal
Normalized name: Nystatin Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin vaginal tablets (100,000 units each) administered twice daily for 15 days
Study: 28126581
Drug: CAMS (Collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMS (Collaborative Assessment and Management of Suicidality) therapy
Study: 28126581
Drug: Usual intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual intensive inpatient treatment (Control)
Study: 26025994
Drug: Levalbuterol 1.25
Normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 1.25 mg three times daily
Study: 26025994
Drug: Albuterol 2.5
Normalized name: levalbuterol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 2.5 mg four times daily
Study: 22978252
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of beclomethasone (BDP) 50μg and formoterol 6μg (Foster® pMDI)
Study: 22978252
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of BDP 200μg and formoterol 24μg
Study: 19011437
Drug: Bilastine 40
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 40 mg
Study: 18241919
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with thalidomide (TAD)
Study: 18241919
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with adriamycin and dexamethasone in combination with vincristin (VAD)
Study: 18241919
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with bortezomib (PAD)
Study: 18241919
Drug: Post-ASCT (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-ASCT (after high-dose melphalan and autologous stem cell transplant)
Study: 18241919
Drug: Pre-treatment levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment levels of VWF, fibrinogen and FVIII:C
Study: 18241919
Drug: Coagulation factor
Normalized name: Coagulation factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation factor abnormalities before and during treatment
Study: 31437124
Drug: Aromatherapy (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (inhalation of essential oil blend)
Study: 21045083
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg orally daily until disease progression
Study: 21045083
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg orally daily
Study: 15661436
Drug: Morphine exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine exposure since birth
Study: 11873239
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous IL-2 therapy
Study: 11873239
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous IL-2 therapy
Study: 11873239
Drug: Subcutaneous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-2 therapy
Study: 11873239
Drug: All IL-2
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All IL-2 therapies
Study: 16273644
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (Sb) 0.5 g bid PO for 6 days
Study: 7913906
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 250 micrograms somatostatin
Study: 7913906
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of somatostatin after bolus injection
Study: 27541442
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminders and free topical corticosteroid medication
Study: 27541442
Drug: Standard follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard follow-up without reminders or free medication
Study: 24894197
Drug: Selenium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium administration
Study: 22048460
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily for weeks 2-8)
Study: 11599686
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza vaccine (FLU-AD; n = 204)
Study: 11599686
Drug: Conventional subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subunit influenza vaccine (AGRIPPAL S1; n = 104)
Study: 9844794
Drug: Pergolide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (mean final dose, 2.8 mg daily)
Study: 9844794
Drug: Levodopa (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (mean final dose, 435 mg daily)
Study: 7986226
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to histone (H2A-H2B)-DNA complexes in patients with scleroderma-related disorders
Study: 7986226
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to histone (H2A-H2B)-DNA complexes in patients with systemic lupus erythematosus (SLE)
Study: 28107765
Drug: Conventional colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional colonoscopy with right‐colon retroflexion (CC/R)
Study: 20445570
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Angiotensin II receptor blocker
Study: 20445570
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Diuretics
Study: 18460481
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2 capsules of 1 gm per day)
Study: 18460481
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (2 capsules of 1 gm per day)
Study: 18460481
Drug: Hempseed oil
Normalized name: OPHIOCORDYCEPS SINENSIS 0.1 g ORAL CAPSULE [HempSeed Cordyceps]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hempseed oil (2 capsules of 1 gm per day)
Study: 18460481
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules of 1 gm per day)
Study: 14674902
Drug: Sitafloxacin 100
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100 mg twice a day
Study: 14674902
Drug: Sparfloxacin 200
Normalized name: sparfloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 200 mg day‐1
Study: 14674902
Drug: Enoxacin 200
Normalized name: enoxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 200 mg three times a day
Study: 14674902
Drug: Levofloxacin 100
Normalized name: levofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 100 mg three times a day
Study: 14674902
Drug: Sitafloxacin 50
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 50 mg twice a day
Study: 6309436
Drug: Amiloride (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10-40 mg/day)
Study: 6309436
Drug: MK-421 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-421 (10 mg/day)
Study: 6309436
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/day) plus MK-421 (10 mg/day)
Study: 27933598
Drug: DHEP mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP mouthwash (0.103% DHEP in aqueous solution)
Study: 27933598
Drug: diclofenac mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac mouthwash (0.074% free diclofenac in aqueous solution)
Study: 7818568
Drug: Tenidap (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap (120 mg/day)
Study: 7016643
Drug: Propranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3 mg/3 min and 0.8 mg/min)
Study: 7016643
Drug: Phentolamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (5 mg stat and 0.5 mg/min)
Study: 31434140
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of ketamine
Study: 31434140
Drug: Ketamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (various applications: intravenous, subcutaneous, intramuscular, intranasal)
Study: 27098290
Drug: 0.1 g·kg‐1BM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g·kg‐1BM of NaHCO3
Study: 27098290
Drug: 0.2 g·kg‐1BM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g·kg‐1BM of NaHCO3
Study: 27098290
Drug: 0.3 g·kg‐1BM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1BM of NaHCO3
Study: 23998788
Drug: Antenatal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal vitamin K1 administration (Group A)
Study: 23998788
Drug: No antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antenatal vitamin K1 administration (Group B)
Study: 21095491
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (recombinant human erythropoietin 4000 IU SC)
Study: 21095491
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (recombinant human erythropoietin 4000 IU SC)
Study: 15705086
Drug: Tolterodine (antimuscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (antimuscarinic drug)
Study: 12939945
Drug: Perftoran and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perftoran and cytoflavin (added to therapy scheme)
Study: 12939945
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (intensive therapy without metabolic antihypoxants)
Study: 6536840
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of potassium chloride
Study: 6536840
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of potassium/magnesium chloride
Study: 6536840
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of potassium-(D,L)-aspartate
Study: 6536840
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of potassium/magnesium-(D,L)-aspartate
Study: 31374218
Drug: Suvorexant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (10 mg week 1, 20 mg week 2)
Study: 29916560
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure medications (specific drugs not mentioned)
Study: 29916560
Drug: Testing medications
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing medications thoroughly in both sexes
Study: 1410147
Drug: Tryptophan-deficient amino
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan-deficient amino acid mixture (4.5 hours before morphine administration)
Study: 1410147
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg intramuscularly)
Study: 3904654
Drug: Triamterene, 50
Normalized name: Triamterene, 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene, 50 to 200 mg daily
Study: 3904654
Drug: Triamterene added
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamterene added to diuretic therapy
Study: 21232723
Drug: Combination-facilitated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-facilitated group (abciximab with half-dose reteplase)
Study: 21232723
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI group (no pre-treatment)
Study: 18081147
Drug: Alexandrite laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alexandrite laser treatment
Study: 15605283
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin 400 mug (group 2)
Study: 15605283
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (group 3)
Study: 11828811
Drug: Long-acting beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta 2-agonists
Study: 9238877
Drug: Mouthrinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinsing with 20 ml distilled water
Study: 29621979
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with volar locking plate
Study: 29621979
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment with cast immobilization
Study: 21656179
Drug: Split-dose polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose polyethylene glycol (PEG) (2 L/2 L)
Study: 21656179
Drug: Split-dose aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose aqueous sodium phosphate (NaP) (45 mL/45 mL, 12 h apart)
Study: 14610480
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (grass pollen immunotherapy)
Study: 10731916
Drug: SS-cream 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.05 gm
Study: 10731916
Drug: SS-cream 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.10 gm
Study: 10731916
Drug: SS-cream 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.15 gm
Study: 10731916
Drug: SS-cream 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.20 gm
Study: 9188946
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (specific immunotherapy)
Study: 12959296
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tablet
Study: 12959296
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablet
Study: 12959296
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg (2 x 250 mg)
Study: 12959296
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg immediately following a standard meal
Study: 29242014
Drug: Omalizumab combined
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab combined with multifood oral immunotherapy (n=36)
Study: 29209154
Drug: Caffeinated supplement
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated supplement
Study: 29209154
Drug: Non-caffeinated supplement
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-caffeinated supplement
Study: 20854954
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus GP IIb/IIIa inhibitor
Study: 20854954
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GP IIb/IIIa inhibitor
Study: 18238736
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 50,000 IU once weekly for 12 weeks
Study: 10776745
Drug: Artemether 6
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether 6 mg/kg orally six times once every 3 weeks
Study: 10776745
Drug: Artemether 6
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether 6 mg/kg
Study: 11885225
Drug: Self brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self brushing with acidulated phosphate fluoride (APF) gel (pH 5.6; concentration: 4520 ppm of ion F‐)
Study: 23763894
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder
Study: 17692744
Drug: BG9928 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (3, 15, 75, or 225 mg)
Study: 17692744
Drug: BG9928 (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (15, 75, or 225 mg)
Study: 17692744
Drug: BG9928 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (3 to 225 mg)
Study: 15174010
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPD) 0.4 mg/kg orally
Study: 15174010
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPD) 0.4 mg/kg orally coadministered with levodopa (0.5 mg/kg/hr)
Study: 2412045
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg i.v.)
Study: 2102133
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg/b.i.d.)
Study: 28768250
Drug: L. gasseri
Normalized name: Lactobacillus crispatus/L. gasseri/L. jensenii/L. rhamnosus 5 billion cell ORAL CAPSULE
DrugBank: Lactobacillus gasseri (DB16543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. gasseri OLL2716 group
Study: 1661645
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.07 units/kg at night)
Study: 7041324
Drug: Carbimazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 80 mg daily for two months
Study: 29623143
Drug: Nalbuphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (15 μg·kg‐1·ml‐1) with flurbiprofen
Study: 25149899
Drug: Needle aponeurotomy
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle aponeurotomy combined with triamcinolone injections
Study: 20074380
Drug: Agarose gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agarose gel electrophoresis
Study: 16026123
Drug: Concomitant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant drugs
Study: 11802045
Drug: Ketoprofen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (0.5 mg/kg bolus intravenously, followed by 3 mg/kg continuous infusion over 24 hours, and 3 to 5 mg/kg per day at home)
Study: 11802045
Drug: Ketoprofen combined
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen combined with paracetamol-codeine
Study: 11802045
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and oxycodone (control group)
Study: 2269542
Drug: DPI 201‐106
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI 201‐106 (20 mg)
Study: 2269542
Drug: DPI 201‐106
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI 201‐106 (40 mg)
Study: 6308702
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg i.v.)
Study: 6308702
Drug: Apomorphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (20 micrograms/kg/hr) for 40 min by i.v. infusion
Study: 28799413
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Treatment for Depression (BATD-HIV)
Study: 26857924
Drug: Standard concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL regimen)
Study: 26857924
Drug: Experimental sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental sequential bevacizumab given 4 days before chemotherapy
Study: 23218935
Drug: Bupivacaine .5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine .5% with ketorolac .6 mg/hour